GlassScriptPhysician profile
Janice M Lofft
NPI 1124655220
$2,312.78
in general payments reported to CMS, 2019-2025
35 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $427 · 2023: $479 · 2024: $724 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $258.93 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Teva Pharmaceuticals USA, INC. | $191.51 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Collegium Pharmaceutical, INC. | $156.00 | 2022-2025 | Belbuca |
| Vertos Medical, INC. | $142.42 | 2022-2024 | Mild Device Kit |
| Abbvie INC. | $140.88 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $139.20 | 2023-2025 | Ongentys, Rytary |
| Scilex Pharmaceuticals INC. | $114.25 | 2022-2025 | |
| Emd Serono, INC. | $103.79 | 2023-2024 | Mavenclad |
| Nevro Corp. | $99.39 | 2022-2023 | Senza |
| Takeda Pharmaceuticals U.S.A., INC. | $83.22 | 2024 | Hyqvia |
| Lilly USA, LLC | $80.00 | 2021-2024 | Amyvid, Emgality |
| Averitas Pharma INC. | $78.23 | 2023-2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $70.57 | 2023-2024 | Ultomiris |
| Ucb, INC. | $55.35 | 2021-2025 | Nayzilam, Briviact |
| Sk Life Science, INC. | $52.49 | 2022-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $48.65 | 2022 | |
| Grt US Holding, INC. | $48.21 | 2022 | |
| Argenx US, INC. | $48.02 | 2022-2025 | Vyvgart Hytrulo |
| Acorda Therapeutics, INC | $45.76 | 2024 | Inbrija |
| Lundbeck LLC | $45.10 | 2021-2024 | Vyepti |
| Csl Behring | $34.85 | 2023 | Hizentra |
| Upsher-Smith Laboratories LLC | $31.28 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $27.70 | 2024 | Ingrezza |
| Orthofix Medical, INC. | $24.92 | 2025 | Cervical-Stim |
| Pfizer INC. | $24.32 | 2023 | |
| Convatec INC. | $19.16 | 2025 | |
| Amgen INC. | $18.53 | 2023 | Aimovig |
| Medtronic, INC. | $18.30 | 2023 | Synchromedii |
| Banner Life Sciences, LLC | $17.21 | 2022 | |
| Acadia Pharmaceuticals INC | $16.96 | 2022 | |
| Tonix Medicines, INC. | $16.53 | 2025 | Zembrace Symtouch |
| Kowa Pharmaceuticals America, INC. | $16.47 | 2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $15.78 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.76 | 2022 | |
| Neurelis, INC. | $14.04 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janice Lofft listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.